669 860
Table 1 – Intraductal carcinoma (IDC), cribriform architecture (CA), and percentage of genome alteration (PGA) are prognostic for biochemical relapse in the Canadian intermediate-risk and
MSKCC cohorts
Univariable (
N
= 531, events = 142)
Multivariable (clinical + IDC/CA;
N
= 531,events = 142);Harrell’s C-
index = 0.642 (95% CI = 0.534–0.75)
Multivariable (clinical + IDC/CA + PGA;
N
= 215,events = 98);Harrell’s C-
index = 0.652 (95% CI = 0.547–0.758)
Canadian intermediate-risk cohort
HR (95% CI)
p
value
HR (95% CI)
p
value
HR (95% CI)
p
value
Age (continuous)
1.01 (0.98–1.04)
0.51
–
–
[3_TD$DIFF]
cT
[1_TD$DIFF]
category
cT2b/c vs cT1/T2a (ref.)
1.57 (1.08–2.29)
0.018
1.36 (0.93–1.99)
0.11
1.32 (0.83–2.1)
0.23
GS
7 vs 6 (ref.)
0.97 (0.56–1.71)
0.93
–
–
ISUP grade
2 vs 1 (ref.)
0.9 (0.51–1.6)
0.73
–
–
3 vs 1
1.17 (0.63–2.17)
0.62
–
–
PSA (continuous)
1.05 (1.01–1.10)
0.019
1.06 (1.01–1.1)
0.013
1.07 (1.02–1.13)
0.011
IDC/CA
Present vs absent
2.17 (1.54–3.06)
<
0.001
2.17 (1.53–3.07)
<
0.001
1.98 (1.29–3.04)
0.0017
PGA (continuous)
1.03 (1.01–1.06)
0.0072
1.03 (1–1.05)
0.05
Univariable (
N
= 258,events = 71)
Multivariable (clinical + IDC/CA;
N
= 234,events = 65);Harrell’s C-
index = 0.739 (95% CI = 0.638–0.839)
Multivariable (clinical + IDC/CA + PGA;
N
= 234, events = 65);Harrell’s C-
index = 0.745 (95% CI = 0.644–0.845)
MSKCC cohort
HR (95% CI)
p
value
HR (95% CI)
p
value
HR (95% CI)
p
value
Age (continuous)
1.03 (1–1.07)
0.075
–
–
[3_TD$DIFF]
cT
[1_TD$DIFF]
category
cT2b/c vs cT1/T2a (ref.)
1.23 (0.71–2.14)
0.46
1.08 (0.59–1.98)
0.81
1.12 (0.61–2.07)
0.71
cT3 vs cT1/2a (ref.)
4.92 (2.3–10.54)
<
0.001
3.18 (1.39–7.24)
0.0059
3.33 (1.46–7.61)
0.0043
GS
7 vs 6 (ref.)
2.58 (1.49–4.48)
<
0.001
–
–
8/9 vs 6 (ref.)
5.07 (2.66–9.65)
<
0.001
–
–
ISUP grade
2 vs 1 (ref.)
1.92 (1.03–3.58)
0.04
1.52 (0.77–2.97)
0.23
1.54 (0.79–3.01)
0.21
3 vs 1
5.0 (2.52–9.94)
<
0.001
3.54 (1.61–7.78)
0.0017
3.41 (1.55–7.51)
0.0023
4/5 vs 1
5.12 (2.69–9.76)
<
0.001
2.99 (1.43–6.27)
0.0036
2.7 (1.26–5.8)
0.011
PSA (continuous)
1.01 (1–1.01)
<
0.001
1 (1–1.01)
0.013
1 (1–1.01)
0.012
IDC/CA
Present vs absent
3.11 (1.83–5.3)
<
0.001
2.32 (1.32–4.08)
0.0035
1.86 (0.97–3.56)
0.063
PGA (continuous)
1.07 (1.04–1.1)
<
0.001
1.03 (0.99–1.07)
0.15
CI = confidence interval; GS = Gleason score; HR = hazards ratio; ISUP = International Society of Urological Pathology grading system for prostate cancer based on GS; MSKCC = Memorial Sloan Kettering Cancer Center;
PSA = prostate-specific antigen; ref. = reference.
Harrell’s C-indices for the multivariable clinical only model were 0.582 (95% CI = 0.474–0.69) in the Canadian cohort, and 0.715 (95% CI = 0.615–0.815) in the MSKCC cohort.
E U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) 6 6 5 – 6 7 4
669